luteolin 4'-O-phosphate | 501445-18-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: luteolin 4'-O-phosphate
• 英文别名: 3',5,7-Trihydroxyflavone-4'-phosphate；[4-(5,7-Dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenyl] dihydrogen phosphate
• CAS: 501445-18-7
• 化学式: C₁₅H₁₁O₉P
• 分子量: 366.221
• InChiKey: XVLCACCWSOXKOL-UHFFFAOYSA-N

物化性质

• 沸点：
  723.0±70.0 °C(Predicted)
• 密度：
  1.820±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  154
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  木犀草素 在 phosphotransferase from Bacillus subtilis 、 5’-三磷酸腺苷 、 sodium chloride 、 magnesium chloride 作用下， 以 二甲基亚砜 为溶剂， 反应 1.0h， 生成 luteolin 4'-O-phosphate 、 luteolin 3-O-phosphate
  参考文献：
  名称：

  Discovery of a novel phosphotransferase from Bacillus subtilis that phosphorylates a broad spectrum of flavonoids

  摘要：

  DOI：

  10.1016/j.foodchem.2022.134001

文献信息

• Inhibition by 3-deoxyflavonoids of T-lymphocyte activation and therapies related thereto
  申请人：——

  公开号：US20040102386A1

  公开（公告）日：2004-05-27

  3-Deoxyflavonoid compounds and methods for inhibiting T-cell activity and treating diseases and disorders (e.g., autoimmune disorders, inflammatory disorders, diabetes, ALS, MS, rheumatoid arthritis, etc.). In some cases the efficacy and/or duration of action of luteolin and/or other 3-deoxyflavonoid compounds may be increased by administering such compounds along with Rutin, a Rutin congener and/or a Rutin derivative. Also, in some cases, first pass metabolism of luteolin or other 3-deoxyflavonoids may be avoided by administering such compounds by parenteral routes (e.g., routes wherein absorption occurs at sites other than the stomach or intestinal mucosa, such as sublingual, buccal, intranasal, injection, etc.).

  3-去氧黄酮类化合物和用于抑制T细胞活性和治疗疾病和障碍（例如自身免疫性疾病、炎症性疾病、糖尿病、肌萎缩侧索硬化症、多发性硬化症、类风湿性关节炎等）的方法。在某些情况下，通过与芦丁、芦丁同系物和/或芦丁衍生物一起给予这些化合物，可以增加槲皮素和/或其他3-去氧黄酮类化合物的功效和/或作用持续时间。此外，在某些情况下，通过经肠外途径（例如舌下、颊黏膜、鼻内、注射等吸收发生在胃或肠粘膜以外的部位的途径）给予这些化合物，可以避免槲皮素或其他3-去氧黄酮类化合物的首过代谢。
• EP1429750A4
  申请人：——

  公开号：EP1429750A4

  公开（公告）日：2005-08-03
• INHIBITION BY 3-DEOXYFLAVONOIDS OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO
  申请人：Synorx, Inc.

  公开号：EP1429750A2

  公开（公告）日：2004-06-23
• US6774142B2
  申请人：——

  公开号：US6774142B2

  公开（公告）日：2004-08-10
• [EN] INHIBITION BY 3-DEOXYFLAVONOIDS OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO<br/>[FR] INHIBITION DE L'ACTIVATION DE LYMPHOCYTES T PAR DES 3-DEOXYFLAVONOIDES ET THERAPIES ASSOCIEES
  申请人：SYNORX INC

  公开号：WO2003022994A2

  公开（公告）日：2003-03-20

  3-Deoxyflavonoid compounds and methods for inhibiting T-cell activity and treating diseases and disorders (e.g., autoimmune disorders, inflammatory disorders, diabetes, ALS, MS, rheumatoid arthritis, etc.). In some cases the efficacy and/or duration of action of luteolin and/or other 3-deoxyflavonoid compounds may be increased by administering such compounds along with Rutin, a Rutin congenor and/or a Rutin derivative. Also, in some cases, first pass metabolism of luteolin or other 3-deoxyflavonoids may be avoided by administering such compounds by parenteral routes (e.g., sublingual, buccal, intranasal, injection, etc.).